u/LesBattersby17

Author argues MYNZ is a focused molecular diagnostics bet whose ColoAlert EU distribution expansion in the UK, Switzerland, and Germany can become a real revenue base while Quest Diagnostics acts as central lab for the 2026 U.S. ReconAAsense pivotal and holds an 18-month commercialization option. If Europe ramps, U.S. feasibility completes in 1H26 with the pivotal starting in 2026 and approval follows, the author sees a multi-year re-rating with the pancreatic program as a second growth axis. Main stated risks are financing/dilution, regulatory delays or misses, single-asset concentration in colorectal cancer, commercial adoption disappointment, and a low-premium takeout capping upside.

Author argues AI data-center load growth is tightening the grid and turning on-site resilience into a separate, non-discretionary spend category for hospitals and other mission-critical facilities. They highlight NextNRG (NXXT) as not a pure-play utility but as exposed through 28-year healthcare microgrid PPAs (solar, storage, controls with no upfront capex) and EzFill mobile fueling for generator logistics. They cite December 2025 preliminary operational numbers of about $8.01M revenue, up 253% y/y, and about 2.53M gallons delivered, up 308% y/y, plus an A123 MOU referencing 20-foot, 5 MWh battery storage units. Main stated risk is disclosed lender litigation around an alleged default, which could affect financing, dilution, or project execution.